Abstract
Introduction: Concerns were raised about a high occurrence of hepatocellular carcinoma (HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals (DAAs). Areas covered: The authors summarize the clinical studies reporting the occurrence rate and risk factors of HCC after DAAs in CHC. Expert opinion: The recent introduction of all-oral DAAs has substantially changed the scenario of CHC, achieving a sustained virological response (SVR) in >90% of cases. Earlier concerns raised about an increasing incidence of HCC post-DAAs were flawed by large heterogeneity of patients, the limited number of well-designed prospective studies (only nine, up to date) and the inclusion of a large number of patients with advanced liver disease, previously excluded from interferon-based studies. Current data on DAAs have shown a lower risk of HCC development; however, they were unable to identify patients at greater risk for HCC occurrence after SVR. Surveillance strategy, likely lifelong, is mandatory in these patients according to general expert opinion.
| Original language | English |
|---|---|
| Pages (from-to) | 603-610 |
| Number of pages | 8 |
| Journal | Expert Opinion on Drug Safety |
| Volume | 18 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 3 2019 |
Fingerprint
Keywords
- DAA/direct-acting antivirals
- HCC
- HCV
- Hepatocellular carcinoma
- occurrence
ASJC Scopus subject areas
- Pharmacology (medical)
Cite this
Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection : literature review and risk analysis. / Galati, Giovanni; Muley, Moises; Viganò, Mauro; Iavarone, Massimo; Vitale, Alessandro; Dell’Unto, Chiara; Lai, Quirino; Cabibbo, Giuseppe; Sacco, Rodolfo; Villa, Erica; Trevisani, Franco.
In: Expert Opinion on Drug Safety, Vol. 18, No. 7, 03.07.2019, p. 603-610.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Occurrence of hepatocellular carcinoma after direct-acting antiviral therapy for hepatitis C virus infection
T2 - literature review and risk analysis
AU - Galati, Giovanni
AU - Muley, Moises
AU - Viganò, Mauro
AU - Iavarone, Massimo
AU - Vitale, Alessandro
AU - Dell’Unto, Chiara
AU - Lai, Quirino
AU - Cabibbo, Giuseppe
AU - Sacco, Rodolfo
AU - Villa, Erica
AU - Trevisani, Franco
PY - 2019/7/3
Y1 - 2019/7/3
N2 - Introduction: Concerns were raised about a high occurrence of hepatocellular carcinoma (HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals (DAAs). Areas covered: The authors summarize the clinical studies reporting the occurrence rate and risk factors of HCC after DAAs in CHC. Expert opinion: The recent introduction of all-oral DAAs has substantially changed the scenario of CHC, achieving a sustained virological response (SVR) in >90% of cases. Earlier concerns raised about an increasing incidence of HCC post-DAAs were flawed by large heterogeneity of patients, the limited number of well-designed prospective studies (only nine, up to date) and the inclusion of a large number of patients with advanced liver disease, previously excluded from interferon-based studies. Current data on DAAs have shown a lower risk of HCC development; however, they were unable to identify patients at greater risk for HCC occurrence after SVR. Surveillance strategy, likely lifelong, is mandatory in these patients according to general expert opinion.
AB - Introduction: Concerns were raised about a high occurrence of hepatocellular carcinoma (HCC) after successful treatment of chronic hepatitis C (CHC) by direct-acting antivirals (DAAs). Areas covered: The authors summarize the clinical studies reporting the occurrence rate and risk factors of HCC after DAAs in CHC. Expert opinion: The recent introduction of all-oral DAAs has substantially changed the scenario of CHC, achieving a sustained virological response (SVR) in >90% of cases. Earlier concerns raised about an increasing incidence of HCC post-DAAs were flawed by large heterogeneity of patients, the limited number of well-designed prospective studies (only nine, up to date) and the inclusion of a large number of patients with advanced liver disease, previously excluded from interferon-based studies. Current data on DAAs have shown a lower risk of HCC development; however, they were unable to identify patients at greater risk for HCC occurrence after SVR. Surveillance strategy, likely lifelong, is mandatory in these patients according to general expert opinion.
KW - DAA/direct-acting antivirals
KW - HCC
KW - HCV
KW - Hepatocellular carcinoma
KW - occurrence
UR - http://www.scopus.com/inward/record.url?scp=85067605582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067605582&partnerID=8YFLogxK
U2 - 10.1080/14740338.2019.1617272
DO - 10.1080/14740338.2019.1617272
M3 - Review article
VL - 18
SP - 603
EP - 610
JO - Expert Opinion on Drug Safety
JF - Expert Opinion on Drug Safety
SN - 1474-0338
IS - 7
ER -